Post-Authorisation Safety Study (PASS) of CLAIRYG® (Human normal immunoglobulin for intravenous use) in children under 12 years treated for primary immunodeficiency (PID) or immune thrombocytopenic purpura (ITP) (IGNGPASSP) First published 22/05/2020 Last updated 23/04/2024 EU PAS number:EUPAS33320 Study Finalised